{"filing":{"accession_number":"0001648257-26-000059","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"hcm-20260924x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000059/hcm-20260924x6k.htm"},"events":[{"id":34706,"run_id":31951,"accession_number":"0001648257-26-000059","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces that HUTCHMED will present clinical data from multiple studies at the ESMO Congress 2026, including positive Phase III results from the SAFFRON and SANOVO studies evaluating savolitinib and osimertinib combination therapy. The disclosure highlights two late-breaking abstracts selected for oral presentations at a major medical conference, demonstrating clinical progress in the company's pipeline. While not a discrete M\u0026A, financial, or governance event, this represents a material operational/clinical milestone that would affect investor assessment of the company's drug development progress and commercial prospects.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-09-24","form":"6-K","submitted_at":null,"items":[{"id":38526,"accession_number":"0001648257-26-000059","item_number":"EX-99.1","item_title":"hcm-20260924xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces that HUTCHMED will present clinical data from multiple studies at the ESMO Congress 2026, including positive Phase III results from the SAFFRON and SANOVO studies evaluating savolitinib and osimertinib combination therapy. The disclosure highlights two late-breaking abstracts selected for oral presentations at a major medical conference, demonstrating clinical progress in the company's pipeline. While not a discrete M\u0026A, financial, or governance event, this represents a material operational/clinical milestone that would affect investor assessment of the company's drug development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:19:38.611072+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38526,"accession_number":"0001648257-26-000059","item_number":"EX-99.1","item_title":"hcm-20260924xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces that HUTCHMED will present clinical data from multiple studies at the ESMO Congress 2026, including positive Phase III results from the SAFFRON and SANOVO studies evaluating savolitinib and osimertinib combination therapy. The disclosure highlights two late-breaking abstracts selected for oral presentations at a major medical conference, demonstrating clinical progress in the company's pipeline. While not a discrete M\u0026A, financial, or governance event, this represents a material operational/clinical milestone that would affect investor assessment of the company's drug development progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:19:38.611072+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-09-24"}]}